Breast cancer is a heterogeneous disease, and the different subtypes can be defined by the immunohistochemical (IHC) approach based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) and Ki-67 expression levels [1–3]. This evidence concerns the gene PGR and breast carcinoma.